Skip to main content

Animations

MJFF Publications

3241 - 3250 of 8587 Results
Title
Year
  • Year
  • 2018
  • 2018
  • 2015
  • 2015
  • 2023
  • 2016
  • 2016
  • 2015
  • 2024
  • 2016
  • Summary Details
    OPEN
    Title: Post hoc analysis of the Exenatide‐PD trial—Factors that predict response
    Journal Name: European Journal of Neuroscience
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/ejn.14096
    Best OA location URL:
    Citation Count: 60
  • Summary Details
    OPEN
    Title: The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/acn3.644
    Citation Count: 472
  • Summary Details
    OPEN
    Title: Network structure of brain atrophy in de novo Parkinson's disease
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.7554/elife.08440
    Citation Count: 232
  • Summary Details
    OPEN
    Title: Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils
    Journal Name: Journal of Medicinal Chemistry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jmedchem.5b00571
    Best OA location URL:
    Citation Count: 106
  • Summary Details
    OPEN
    Title: Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2023.1069411
    Citation Count: 42
  • Summary Details
    RESTRICTED
    Title: Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26597
    Best OA location URL:
    Citation Count: 72
  • Summary Details
    RESTRICTED
    Title: A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26659
    Best OA location URL:
    Citation Count: 130
  • Summary Details
    OPEN
    Title: Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26170
    Citation Count: 278
  • Summary Details
    OPEN
    Title: iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1073/pnas.2314604121
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
    Journal Name: The FASEB Journal
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1096/fj.201600816r
    Citation Count: 356
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.